Severe Jennifer, Greden John F, Reddy Priyanka
Department of Psychiatry, University of Michigan, Ann Arbor.
Focus (Am Psychiatr Publ). 2020 Apr;18(2):120-128. doi: 10.1176/appi.focus.20200008. Epub 2020 Apr 23.
According to the World Health Organization, major depressive disorder is the world's leading cause of disability. If clinical remission is not attained and sustained, episodes tend to recur with greater severity and with lessening responsivity to conventional treatments. Reasonably well-established clues and guidelines are presented about the high risk and profound consequences of recurrence of major depressive disorder if successful antidepressant treatments are discontinued. The authors describe actions required to achieve a "lifetime wellness" focus for treatment. Current approaches would need to be transformed from attainment of clinical remission to attainment and maintenance of lifetime wellness, with the knowledge that some individuals may need continuous treatment. Risk factors would need to be assessed and used to formulate clinical treatment guidelines for risk of recurrence. Clinical trials would need to be greatly lengthened. Measurement-based care and precision medicine would be the foundation for informing clinical decisions. The authors provide guidance in determining how to discontinue antidepressants if that decision is made despite risks.
根据世界卫生组织的数据,重度抑郁症是全球致残的主要原因。如果无法实现并维持临床缓解,病情发作往往会更严重地复发,且对传统治疗的反应性会降低。关于停用成功的抗抑郁治疗后重度抑郁症复发的高风险和严重后果,已有相当完善的线索和指南。作者描述了为实现以“终身健康”为重点的治疗所需采取的行动。当前的治疗方法需要从实现临床缓解转变为实现并维持终身健康,因为要知道有些患者可能需要持续治疗。需要评估风险因素并用于制定复发风险的临床治疗指南。临床试验的时长需要大幅延长。基于测量的护理和精准医学将成为指导临床决策的基础。作者提供了关于如果不顾风险做出停药决定时如何停药的指导。